CoChat
Sign Up
Cited by 94

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Oncofetal reprogramming in tumour development and progression

Sharma, Ankur, Blériot, Camille, Currenti, Jennifer, Ginhoux, Florent·2022·Nature Reviews Cancer
DOI 10.1038/s41568-022-00497-8
Open this paper in CoChat — free account

Abstract

Embryonic development is characterized by rapidly dividing cells, cellular plasticity and a highly vascular microenvironment. These features are similar to those of tumour tissue, in that malignant cells are characterized by their ability to proliferate and exhibit cellular plasticity. The tumour microenvironment also often includes immunosuppressive features. Reciprocal communication between various cellular subpopulations enables fetal and tumour tissues to proliferate, migrate and escape immune responses. Fetal-like reprogramming has been demonstrated in the tumour microenvironment, indicating extraordinary cellular plasticity and bringing an additional layer of cellular heterogeneity. More importantly, some of these features are also present during inflammation. This Perspective discusses the similarity between embryogenesis, inflammation and tumorigenesis, and describes the mechanisms of oncofetal reprogramming that enable tumour cells to escape from immune responses, promoting tumour growth and metastasis.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41568-022-00497-8

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 158

  1. Ma, Y. et al. The relationship between early embryo development and tumourigenesis. J. Cell Mol. Med. 14, 2697–2701 (2010). · DOI
  2. Manzo, G. Similarities between embryo development and cancer process suggest new strategies for research and therapy of tumors: a new point of view. Front. Cell Dev. Biol. 7, 20 (2019). · DOI
  3. Kerosuo, L. & Bronner-Fraser, M. What is bad in cancer is good in the embryo: importance of EMT in neural crest development. Semin. Cell Dev. Biol. 23, 320–332 (2012). · DOI
  4. Caramel, J. et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 24, 466–480 (2013). · DOI
  5. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011). · DOI · Paper page
  6. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013). · DOI · Paper page
  7. Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377–394.e21 (2020). · DOI · Paper page
  8. Suvà, M. L. & Tirosh, I. Single-cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol. Cell 75, 7–12 (2019). · DOI
  9. Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624.e24 (2017). · DOI · Paper page
  10. Smith, E. A. & Hodges, H. C. The spatial and genomic hierarchy of tumor ecosystems revealed by single-cell technologies. Trends Cancer 5, 411–425 (2019). · DOI
  11. Ungefroren, H., Sebens, S., Seidl, D., Lehnert, H. & Hass, R. Interaction of tumor cells with the microenvironment. Cell Commun. Signal. 9, 18 (2011). · DOI · Paper page
  12. Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015). · DOI
  13. Ramachandran, P. et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512–518 (2019). · DOI · Paper page
  14. Flier, J. S., Underhill, L. H. & Dvorak, H. F. Tumors: wounds that do not heal. N. Engl. J. Med. 315, 1650–1659 (1986). · DOI · Paper page
  15. Rodrigues, M., Kosaric, N., Bonham, C. A. & Gurtner, G. C. Wound healing: a cellular perspective. Physiol. Rev. 99, 665–706 (2019). · DOI
  16. Deyell, M., Garris, C. S. & Laughney, A. M. Cancer metastasis as a non-healing wound. Br. J. Cancer 124, 1491–1502 (2021). · DOI
  17. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008). · DOI · Paper page
  18. Hayashi, P. H. & Zeldis, J. B. Molecular biology of viral hepatitis and hepatocellular carcinoma. Compr. Ther. 19, 188–196 (1993).
  19. Pera, M. et al. Barrett’s disease: pathophysiology of metaplasia and adenocarcinoma. Ann. Thorac. Surg. 56, 1191–1197 (1993). · DOI
  20. Bedwani, R. et al. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br. J. Cancer 77, 1186–1189 (1998). · DOI
  21. Choi, P. M. & Zelig, M. P. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35, 950–954 (1994). · DOI
  22. Toller, I. M. et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc. Natl Acad. Sci. USA 108, 14944–14949 (2011). · DOI
  23. Aguilar-Cazares, D. et al. Contribution of angiogenesis to inflammation and cancer. Front. Oncol. 9, 1399 (2019). · DOI
  24. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818–829 (2008). · DOI
  25. Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128–134 (2018). · DOI · Paper page
  26. Stone, R. C. et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 365, 495–506 (2016). · DOI
  27. Yan, C. et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-α through bone morphogenic protein-2. Am. J. Pathol. 176, 2247–2258 (2010). · DOI
  28. Rosenblum, D. & Naik, S. New dog, old tricks: developmental programs resurface in inflammation. Cell Stem Cell 28, 592–594 (2021). · DOI
  29. Zhu, X. et al. Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention. Signal. Transduct. Target. Ther. 6, 245 (2021). · DOI
  30. Kundu, J. K. & Surh, Y.-J. Inflammation: gearing the journey to cancer. Mutat. Res. 659, 15–30 (2008). · DOI
  31. Lillie, F. R. The Development of the Chick: an Introduction to Embryology, 2nd edn. (Henry Holt, 1908). · DOI
  32. Abelev, G. I., Perova, S. D., Khramkova, N. I., Postnikova, Z. A. & Irlin, I. S. Production of embryonal α-globulin by transplantable mouse hepatomas. Transplantation 1, 174–180 (1963). · DOI
  33. Gold, P. & Freedman, S. O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122, 467–481 (1965). · DOI
  34. Schapira, F., Dreyfus, J.-C. & Schapira, G. Anomaly of aldolase in primary liver cancer. Nature 200, 995–997 (1963). · DOI
  35. Banwo, O., Versey, J. & Hobbs, J. R. New oncofetal antigen for human pancreas. Lancet 303, 643–645 (1974). · DOI
  36. Laurence, D. J. R. et al. Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma. Br. Med. J. 3, 605–609 (1972). · DOI
  37. Marchand, A., Fenoglio, C. M., Pascal, R., Richart, R. M. & Bennett, S. Carcinoembryonic antigen in human ovarian neoplasms. Cancer Res. 35, 3807–3810 (1975).
  38. Neufeld, L. et al. Carcinoembryonic antigen in the diagnosis of prostate carcinoma. Oncology 29, 376–381 (1974). · DOI
  39. Trevisani, F., Garuti, F. & Neri, A. Alpha-fetoprotein for diagnosis, prognosis, and transplant selection. Semin. Liver Dis. 39, 163–177 (2019). · DOI
  40. Galle, P. R. et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 39, 2214–2229 (2019). · DOI · Paper page
  41. McIntire, K. R., Waldmann, T. A., Moertel, C. G. & Go, V. L. Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 35, 991–996 (1975).
  42. Kashala, L. O., Kalengayi, M. M. R. & Essex, M. Alpha-fetoprotein synthesis in human hepatocellular carcinoma: correlation with hepatitis B surface antigen expression. Cancer Invest. 10, 513–522 (2009). · DOI
  43. Abelev, G. I. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv. Cancer Res. 14, 295–358 (1971). · DOI
  44. Ruoslahti, E. & Seppälä, M. Alpha-fetoprotein in cancer and fetal development. Adv. Cancer Res. 29, 275–346 (1979). · DOI
  45. Taketa, K. α-fetoprotein: reevaluation in hepatology. Hepatology 12, 1420–1432 (1990). · DOI
  46. Kew, M. Alpha-fetoprotein in primary liver cancer and other diseases. Gut 15, 814–821 (1974). · DOI
  47. Borras, G., Molina, R., Xercavins, J., Ballesta, A. & Iglesias, J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol. Oncol. 57, 205–211 (1995). · DOI
  48. Screaton, R. A., Penn, L. Z. & Stanners, C. P. Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J. Cell Biol. 137, 939–952 (1997). · DOI
  49. Gold, P. & Goldenberg, N. A. The carcinoembryonic antigen (CEA): past, present, and future. McGill J. Med. 3, 46–66 (2020). · DOI
  50. Panidis, D., Vlassis, G., Matalliotakis, J., Skiadopoulos, S. & Kalogeropoulos, A. Serum levels of the oncofetal antigens CA-125, CA 19-9 and CA 15-3 in patients with endometriosis. J. Endocrinol. Invest. 11, 801–804 (1988). · DOI
  51. Jäger, W., Kissing, A., Cilaci, S., Melsheimer, R. & Lang, N. Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases? Br. J. Cancer 70, 493–495 (1994). · DOI
  52. Bast, R. C. et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331–1337 (1981). · DOI
  53. Jiang, T., Huang, L. & Zhang, S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer 15, 396 (2015). · DOI
  54. Gardner, G. J. et al. CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol. Oncol. 124, 216–220 (2012). · DOI
  55. Fawunmi, D., Gojon, H. & Valachis, A. The effectiveness of ovarian cancer screening in high-risk population and BRCA 1/2 carriers: a systematic review and meta-analysis. J. Clin. Oncol. 31, 1568–1568 (2013). · DOI
  56. May, T. et al. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer. Int. J. Gynecol. Obstet. 140, 247–252 (2018). · DOI
  57. Bella, L., Zona, S., Moraes, G. Nde & Lam, E. W.-F. FOXM1: a key oncofoetal transcription factor in health and disease. Semin. Cancer Biol. 29, 32–39 (2014). · DOI
  58. Müller, S. et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer. Nucleic Acids Res. 48, 8576–8590 (2020). · DOI
  59. Yu, Y. et al. Long non-coding RNA PVT1 promotes cell proliferation and migration by silencing ANGPTL4 expression in cholangiocarcinoma. Mol. Ther. Nucleic Acids 13, 503–513 (2018). · DOI
  60. Cheng, S.-W. et al. Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma. PLoS ONE 8, e80053 (2013). · DOI
  61. Ramos, A. D. et al. Integration of genome-wide approaches identifies lncRNAs of adult neural stem cells and their progeny in vivo. Cell Stem Cell 12, 616–628 (2013). · DOI
  62. Ma, Y. et al. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat. Commun. 3, 1291 (2012). · DOI
  63. Ozaki, T. & Nakagawara, A. role of p53 in cell death and human cancers. Cancers 3, 994–1013 (2011). · DOI · Paper page
  64. Raveh, E., Matouk, I. J., Gilon, M. & Hochberg, A. The H19 long non-coding RNA in cancer initiation, progression and metastasis — a proposed unifying theory. Mol. Cancer 14, 184 (2015). · DOI
  65. Liu, C. et al. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumour Biol. 37, 263–270 (2015). · DOI
  66. Yang, F. et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 279, 3159–3165 (2012). · DOI
  67. Carramusa, L. et al. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J. Cell Physiol. 213, 511–518 (2007). · DOI
  68. Haverty, P. M., Hon, L. S., Kaminker, J. S., Chant, J. & Zhang, Z. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med. Genomics 2, 21 (2009). · DOI
  69. Sircoulomb, F. et al. Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 10, 539 (2010). · DOI
  70. Kamath, A. et al. Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. Cancer Genet. Cytogenet. 183, 117–120 (2008). · DOI
  71. Enciso-Mora, V. et al. A genome-wide association study of Hodgkin’s lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat. Genet. 42, 1126–1130 (2010). · DOI
  72. Schiffman, J. D. et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 70, 512–519 (2010). · DOI
  73. Yu, J. et al. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. Medicine 95, e4436 (2016). · DOI
  74. Song, J. et al. Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma. Biochem. Biophys. Res. Commun. 490, 217–224 (2017). · DOI
  75. Sun, L. et al. H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis. Cancer Sci. 112, 2245–2259 (2021). · DOI
  76. Yang, J. et al. Glycolysis reprogramming in cancer-associated fibroblasts promotes the growth of oral cancer through the lncRNA H19/miR-675-5p/PFKFB3 signaling pathway. Int. J. Oral. Sci. 13, 12 (2021). · DOI
  77. Boyerinas, B. et al. Identification of Let-7–regulated oncofetal genes. Cancer Res. 68, 2587–2591 (2008). · DOI
  78. Nielsen, J. et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell Biol. 19, 1262–1270 (1999). · DOI · Paper page
  79. Yen, B. L. et al. Brief report — human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes. Stem Cell 27, 451–456 (2009). · DOI
  80. Hsu, J.-M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018). · DOI
  81. Corgnac, S. et al. Cancer stem-like cells evade CD8+ CD103+ tumor-resident memory T (TRM) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model. J. Immunother. Cancer 10, e004527 (2022). · DOI
  82. Mintz, B. & Illmensee, K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl Acad. Sci. USA 72, 3585–3589 (1975). · DOI
  83. Pierce, G. B., Pantazis, C. G., Caldwell, J. E. & Wells, R. S. Specificity of the control of tumor formation by the blastocyst. Cancer Res. 42, 1082–1087 (1982).
  84. Lee, L. M. J., Seftor, E. A., Bonde, G., Cornell, R. A. & Hendrix, M. J. C. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev. Dyn. 233, 1560–1570 (2005). · DOI
  85. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018). · DOI · Paper page
  86. Li, H. et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49, 708–718 (2017). · DOI · Paper page
  87. Coorens, T. H. H. et al. Embryonal precursors of Wilms tumor. Science 366, 1247–1251 (2019). · DOI
  88. Behjati, S., Gilbertson, R. J. & Pfister, S. M. Maturation block in childhood cancer. Cancer Discov. 11, 542–544 (2021). · DOI
  89. Jessa, S. et al. Stalled developmental programs at the root of pediatric brain tumors. Nat. Genet. 51, 1702–1713 (2019). · DOI
  90. Dhimolea, E. et al. An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell 39, 240–256.e11 (2021). · DOI
  91. Elenbaas, B. & Weinberg, R. A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264, 169–184 (2001). · DOI
  92. Cassetta, L. & Pollard, J. W. Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17, 887–904 (2018). · DOI
  93. Peng, H. et al. Metabolic reprogramming of vascular endothelial cells: basic research and clinical applications. Front. Cell Dev. Biol. 9, 626047 (2021). · DOI
  94. Becker, L. M. et al. Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer. Cell Rep. 31, 107701 (2020). · DOI
  95. Wei, J., Zheng, W., Chapman, N. M., Geiger, T. L. & Chi, H. T cell metabolism in homeostasis and cancer immunity. Curr. Opin. Biotechnol. 68, 240–250 (2021). · DOI
  96. Verma, V. et al. MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nat. Immunol. 22, 53–66 (2021). · DOI
  97. Tlsty, T. D. Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11, 97–104 (2001). · DOI
  98. Park, C. C., Bissell, M. J. & Barcellos-Hoff, M. H. The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 6, 324–329 (2000). · DOI · Paper page
  99. Li, G. et al. Function and regulation of melanoma–stromal fibroblast interactions: when seeds meet soil. Oncogene 22, 3162–3171 (2003). · DOI
  100. Cassetta, L. et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35, 588–602.e10 (2019). · DOI
  101. Colotta, F., Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073–1081 (2009). · DOI
  102. Bian, Z. et al. Deciphering human macrophage development at single-cell resolution. Nature 582, 571–576 (2020). · DOI
  103. Liu, Z. et al. Fate mapping via ms4a3-expression history traces monocyte-derived cells. Cell 178, 1509–1525.e19 (2019). · DOI · Paper page
  104. Blériot, C., Chakarov, S. & Ginhoux, F. Determinants of resident tissue macrophage identity and function. Immunity 52, 957–970 (2020). · DOI · Paper page
  105. Hashimoto, D., Miller, J. & Merad, M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 35, 323–335 (2011). · DOI
  106. Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921–925 (2014). · DOI
  107. Zhu, Y. et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47, 323–338.e6 (2017). · DOI
  108. Lavine, K. J. et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proc. Natl Acad. Sci. USA 111, 16029–16034 (2014). · DOI · Paper page
  109. Guilliams, M. et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 210, 1977–1992 (2013). · DOI
  110. Schneider, C. et al. Induction of the nuclear receptor PPAR-γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat. Immunol. 15, 1026–1037 (2014). · DOI
  111. Ramos, R. N. et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell 185, 1189–1207.e25 (2022). · DOI
  112. Schor, S. L. et al. Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res. 63, 8827–8836 (2003).
  113. Schor, S. L. et al. Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: effect on hyaluronic acid synthesis. Vitr. Cell Dev. Biol. 25, 737–746 (1989). · DOI
  114. Schor, S. L. & Schor, A. M. Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res. 3, 373–379 (2001). · DOI
  115. Solinas, G. et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 185, 642–652 (2010). · DOI
  116. Zhou, X. et al. Circuit design features of a stable two-cell system. Cell 172, 744–757.e17 (2018). · DOI · Paper page
  117. Rantakari, P. et al. Fetal liver endothelium regulates the seeding of tissue-resident macrophages. Nature 538, 392–396 (2016). · DOI
  118. Aizarani, N. et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature 572, 199–204 (2019). · DOI · Paper page
  119. Kumar, V. et al. Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer. Cancer Discov. 12, 670–691 (2021). · DOI · Paper page
  120. Terkelsen, M. K. et al. Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury. Hepatology 72, 2119–2133 (2020). · DOI
  121. Gomes, R. N., Manuel, F. & Nascimento, D. S. The bright side of fibroblasts: molecular signature and regenerative cues in major organs. NPJ Regen. Med. 6, 43 (2021). · DOI
  122. Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99–115 (2019). · DOI
  123. Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016). · DOI · Paper page
  124. Bu, L. et al. Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene 38, 4887–4901 (2019). · DOI
  125. Schor, S. L. et al. Occurrence of a fetal fibroblast phenotype in familial breast cancer. Int. J. Cancer 37, 831–836 (1986). · DOI
  126. Haggie, J. A., Howell, A., Sellwood, R. A., Birch, J. M. & Schor, S. L. Fibroblasts from relatives of patients with hereditary breast cancer show fetal-like behaviour in vitro. Lancet 329, 1455–1457 (1987). · DOI
  127. Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410–414 (2008). · DOI
  128. Scott, C. L. et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat. Commun. 7, 10321 (2016). · DOI · Paper page
  129. Aegerter, H. et al. Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection. Nat. Immunol. 21, 145–157 (2020). · DOI
  130. Machiels, B. et al. A gammaherpesvirus provides protection against allergic asthma by inducing the replacement of resident alveolar macrophages with regulatory monocytes. Nat. Immunol. 18, 1310–1320 (2017). · DOI
  131. Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312–1326 (2014). · DOI · Paper page
  132. Zhang, Y. et al. Dynamic expression of m6A regulators during multiple human tissue development and cancers. Front. Cell Dev. Biol. 8, 629030 (2021). · DOI
  133. Zaidi, S. K. et al. Bivalent epigenetic control of oncofetal gene expression in cancer. Mol. Cell Biol. 37, e00352-17 (2017). · DOI
  134. Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 (2006). · DOI · Paper page
  135. Azuara, V. et al. Chromatin signatures of pluripotent cell lines. Nat. Cell Biol. 8, 532–538 (2006). · DOI
  136. Ikeda, N. et al. Emergence of immunoregulatory Ym1+Ly6Chi monocytes during recovery phase of tissue injury. Sci. Immunol. 3, eaat0207 (2018). · DOI
  137. Laval, Bde et al. C/EBPβ-dependent epigenetic memory induces trained immunity in hematopoietic stem cells. Cell Stem Cell 26, 657–674.e8 (2020). · DOI
  138. Bastola, S. et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nat. Commun. 11, 4660 (2020). · DOI
  139. Darmanis, S. et al. Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 21, 1399–1410 (2017). · DOI
  140. Casanova-Acebes, M. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 595, 578–584 (2021). · DOI · Paper page
  141. Yao, Y., Li, F., Huang, J., Jin, J. & Wang, H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp. Hematol. Oncol. 10, 39 (2021). · DOI
  142. Schepers, K., Campbell, T. B. & Passegué, E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell 16, 254–267 (2015). · DOI
  143. Lewis, S. M. et al. Spatial omics and multiplexed imaging to explore cancer biology. Nat. Methods 18, 997–1012 (2021). · DOI
  144. Fawkner-Corbett, D. et al. Spatiotemporal analysis of human intestinal development at single-cell resolution. Cell 184, 810–826.e23 (2021). · DOI
  145. Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017). · DOI
  146. diSibio, G. & French, S. W. Metastatic patterns of cancers: results from a large autopsy study. Arch. Pathol. Lab. Med. 132, 931–939 (2008). · DOI
  147. Durante, M. A. et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat. Commun. 11, 496 (2020). · DOI
  148. Mora, J. What is a pediatric tumor? Clin. Oncol. Adolesc. Young-. Adults 2012, 7–15 (2012). · DOI
  149. Gale, K. B. et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc. Natl Acad. Sci. USA 94, 13950–13954 (1997). · DOI
  150. Greaves, M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat. Rev. Cancer 18, 471–484 (2018). · DOI
  151. Gargett, C. E., Nguyen, H. P. T. & Ye, L. Endometrial regeneration and endometrial stem/progenitor cells. Rev. Endocr. Metab. Disord. 13, 235–251 (2012). · DOI
  152. Garcia-Alonso, L. et al. Mapping the temporal and spatial dynamics of the human endometrium in vivo and in vitro. Nat. Genet. 53, 1698–1711 (2021). · DOI
  153. Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020). · DOI · Paper page
  154. Cheng, A.-L. et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann. Oncol. 30, ix186–ix187 (2019). · DOI
  155. Finn, R. S. et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo)+bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J. Clin. Oncol. 39, 267–267 (2021). · DOI
  156. Pachnis, V., Belayew, A. & Tilghman, S. M. Locus unlinked to alpha-fetoprotein under the control of the murine raf and Rif genes. Proc. Natl Acad. Sci. USA 81, 5523–5527 (1984). · DOI
  157. Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854 (1993). · DOI · Paper page
  158. Tang, F. et al. mRNA-seq whole-transcriptome analysis of a single cell. Nat. Methods 6, 377–382 (2009). · DOI · Paper page

Cited by

Sorted by citations

See all 94

Metadata

Authors
Sharma, A., Blériot, C., Currenti, J., & Ginhoux, F.
ORCID
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2022-08-23
Volume
22
Issue
10
Pages
593-602
ISSN
  • 1474-175X
  • 1474-1768
DOI
10.1038/s41568-022-00497-8
Cited by
94
References
23
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review